CD4+ CD45RA+ T cells modulate allergen-induced interleukin 2 responsiveness in human lymphocytes.
Peripheral blood lymphocytes from nonallergic individuals acquired responsiveness to interleukin 2 (IL2) after stimulation with ovalbumin (OVA) or Dermatophagoides farinae (Df) antigens when they were pretreated with the CD45RA antibody, which has been shown to define the suppressor inducer subset of CD4+ cells and also to block its suppressor activity. The effect provided by the CD45RA antibody was lost if the lymphocytes had initially been activated with the OVA of Df antigens. The magnitude of the responses was comparable to the allergen-induced responses observed in OVA- or Df-sensitized lymphocytes from allergic patients. The pre-existing IL2 responsiveness in the patients was not increased by the CD45RA antibody pretreatment. However, the CD45RA antibody pretreatment gave rise to Df-induced IL2 responsiveness in the lymphocytes of the patients sensitized with OVA but not with Df; conversely, OVA-induced IL2 responsiveness was enhanced in Df- but not in OVA-sensitized lymphocytes. The CD45RA antibody apparently acts on CD4+ T cells, but not on CD8+ T cells, to induce the IL2 response. A further dissection of normal CD4+ T cells indicated that CD4+45RA- T cells preferentially respond to IL2 after stimulation with OVA or Df antigens. Since normal CD4+45RA+ T cells did not show antigen-induced IL2 responsiveness even after pretreatment with the CD45RA antibody, it is unlikely that the CD45RA antibody stimulates CD4+45RA+ T cells to become responsive to IL2 after antigenic challenge. Alternatively, CD4+45RA+ T cells may modulate the activity of CD4+45RA- T cells, which are potentially responsive to IL2 by antigenic stimulation and thus provide tolerance in nonallergic lymphocytes. Collectively, a defective suppressor activity of CD4+45RA+ T cells may exist in patients with hen-egg allergy and/or bronchial asthma, which may cause lymphocytes to be hyperreactive to OVA or Df antigens.
Kawano
Y
Y
Department of Pediatrics, Saitama Medical School, Japan.
Noma
T
T
Maeda
K
K
Yata
J
J
D000328:Adult; D000485:Allergens / Q000502:physiology*; D000906:Antibodies / Q000378:metabolism; D000911:Antibodies, Monoclonal; D015703:Antigens, CD / Q000032:analysis* / Q000276:immunology; D039741:Antigens, Dermatophagoides; D015704:CD4 Antigens / Q000032:analysis*; D006649:Histocompatibility Antigens / Q000032:analysis* / Q000276:immunology; D006801:Humans; D006967:Hypersensitivity / Q000097:blood; D007376:Interleukin-2 / Q000502:physiology*; D007700:Kinetics; D017493:Leukocyte Common Antigens; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000648:ultrastructure; D010047:Ovalbumin / Q000494:pharmacology; D015375:Receptors, Interleukin-2 / Q000502:physiology; D016176:T-Lymphocyte Subsets / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*
D000485:Allergens; D000906:Antibodies; D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D039741:Antigens, Dermatophagoides; D015704:CD4 Antigens; D006649:Histocompatibility Antigens; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D010047:Ovalbumin; D017493:Leukocyte Common Antigens